These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
194 related articles for article (PubMed ID: 9579853)
21. [Recent advance in chemotherapy for advanced colorectal cancer]. Aiba K Gan To Kagaku Ryoho; 1996 Apr; 23(5):535-48. PubMed ID: 8678510 [TBL] [Abstract][Full Text] [Related]
22. Raltitrexed ('Tomudex') and radiotherapy can be combined as postoperative treatment for rectal cancer. Botwood N; James R; Vernon C; Price P Ann Oncol; 2000 Aug; 11(8):1023-8. PubMed ID: 11038040 [TBL] [Abstract][Full Text] [Related]
24. Phase II study of raltitrexed ('Tomudex') for patients with advanced soft tissue sarcomas refractory to doxorubicin-containing regimens. Blay JY; Judson I; Rodenhuis S; Hermans C; Smith M; van Glabbeke M; Verweij J Anticancer Drugs; 1999 Nov; 10(10):873-7. PubMed ID: 10630354 [TBL] [Abstract][Full Text] [Related]
25. Raltitrexed, a new drug for advanced colorectal cancer. Mead GM Lancet; 1996 Jun; 347(9015):1568-9. PubMed ID: 8667859 [No Abstract] [Full Text] [Related]
26. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group. Cunningham D; Zalcberg JR; Rath U; Oliver I; van Cutsem E; Svensson C; Seitz JF; Harper P; Kerr D; Perez-Manga G Ann Oncol; 1996 Nov; 7(9):961-5. PubMed ID: 9006748 [No Abstract] [Full Text] [Related]
27. Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations. Jackman AL; Kimbell R; Ford HE Eur J Cancer; 1999 Mar; 35 Suppl 1():S3-8. PubMed ID: 10645207 [TBL] [Abstract][Full Text] [Related]
28. [Absence of cross resistance between an irinotecan plus cisplatin combination and raltitrexed (ZD1694) in two patients with advanced colorectal cancer]. Sato A; Kurihara M; Matsukawa M; Yamazaki T; Shimada K; Endo W; Yamazaki T; Nakamachi M Gan To Kagaku Ryoho; 2000 Apr; 27(4):617-21. PubMed ID: 10791007 [TBL] [Abstract][Full Text] [Related]
29. Continuing the fight against advanced colorectal cancer: new and future treatment options. Bleiberg H Anticancer Drugs; 1998 Jan; 9(1):18-28. PubMed ID: 9491788 [TBL] [Abstract][Full Text] [Related]
30. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331. Ford HE; Mitchell F; Cunningham D; Farrugia DC; Hill ME; Rees C; Calvert AH; Judson IR; Jackman AL Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545 [TBL] [Abstract][Full Text] [Related]
31. Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials. Cunningham D; Zalcberg J; Maroun J; James R; Clarke S; Maughan TS; Vincent M; Schulz J; González Barón M; Facchini T Eur J Cancer; 2002 Mar; 38(4):478-86. PubMed ID: 11872339 [TBL] [Abstract][Full Text] [Related]
32. A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Smith I; Jones A; Spielmann M; Namer M; Green MD; Bonneterre J; Wander HE; Hatschek T; Wilking N; Zalcberg J; Spiers J; Seymour L Br J Cancer; 1996 Aug; 74(3):479-81. PubMed ID: 8695369 [TBL] [Abstract][Full Text] [Related]
33. A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours. Jackman AL; Melin CJ; Kimbell R; Brunton L; Aherne GW; Theti DS; Walton M Biochim Biophys Acta; 2002 Jul; 1587(2-3):215-23. PubMed ID: 12084463 [TBL] [Abstract][Full Text] [Related]
34. Tolerability of Raltitrexed ('Tomudex') in elderly patients with colorectal cancer. Romiti A; Tonini G; Santini D; Di Seri M; Masciangelo R; Mezi S; Verì A; Santuari L; Vincenzi B; Brescia A; Marchei P; Frati L; Tomao S Anticancer Res; 2002; 22(5):3071-6. PubMed ID: 12530045 [TBL] [Abstract][Full Text] [Related]
35. The potential role of Tomudex in the treatment of advanced colorectal cancer. Sobrero AF Tumori; 1997; 83(2):576-80. PubMed ID: 9226024 [TBL] [Abstract][Full Text] [Related]
36. Drug resistance in colon cancer. Gorlick R; Bertino JR Semin Oncol; 1999 Dec; 26(6):606-11. PubMed ID: 10606253 [TBL] [Abstract][Full Text] [Related]
37. [Drug clinics. How I treat. II. Therapeutic approaches to metastatic colorectal cancer]. Jerusalem G; Bours V; Fillet G Rev Med Liege; 1998 Jun; 53(6):318-21. PubMed ID: 9713208 [TBL] [Abstract][Full Text] [Related]
40. [Combination of 5-Fluorouracil and folinic acid--is it still the standard therapy for advanced colorectal carcinoma?]. Carnaghi C; Zucali P; Garassino I Tumori; 2000; 86(5 Suppl 2):S19-25. PubMed ID: 11195298 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]